Distinguished in Midline Lethal Granuloma

Dr. Peter A. Riedell

Hematology Oncology | Hematology | Oncology
The University Of Chicago
5841 S Maryland Ave, 
Chicago, IL 
Accepting New Patients
Offers Telehealth
12 Years of Experience
Distinguished in Midline Lethal Granuloma
The University Of Chicago
5841 S Maryland Ave, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Peter Riedell is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Dr. Riedell has been practicing medicine for over 12 years and is rated as a Distinguished provider by MediFind in the treatment of Midline Lethal Granuloma. His top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Riedell is currently accepting new patients.

His clinical research consists of co-authoring 89 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in IL
Hospital Affiliations
The University Of Chicago Medical Center
Uchicago Medicine Northwest Indiana
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Nippon Life
  • INSURANCE PLAN
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

THE UNIVERSITY OF CHICAGO
5841 S Maryland Ave, Chicago, IL 60637

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) in Adult Patients With Refractory or Relapsed Follicular Lymphoma
A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) in Adult Patients With Refractory or Relapsed Follicular Lymphoma
Enrollment Status: Completed
Publish Date: October 07, 2025
Intervention Type: Biological
Study Drug: Tisagenlecleucel
Study Phase: Phase 2
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: September 30, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Biological, Procedure
Study Drug: Rituximab
Study Phase: Phase 3
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old With Untreated Mantle Cell Lymphoma
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old With Untreated Mantle Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Biological, Drug
Study Drugs: Acalabrutinib, Bendamustine, Bendamustine Hydrochloride, Cytarabine, Rituximab
Study Phase: Phase 2
Phase I/II, Open Label, Multicenter Study of Rapcabtagene Autoleucel in Adult Patients With CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Phase I/II, Open Label, Multicenter Study of Rapcabtagene Autoleucel in Adult Patients With CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2025
Intervention Type: Drug, Biological
Study Drugs: YTB323, Ibrutinib
Study Phase: Phase 1/Phase 2
Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Diffuse Large B Cell Lymphoma (DEEP T CELLS)
Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Diffuse Large B Cell Lymphoma (DEEP T CELLS)
Enrollment Status: Completed
Publish Date: January 20, 2025
Intervention Type: Drug, Biological
Study Drugs: Duvelisib, Tisagenlecleucel
Study Phase: Early Phase 1
A Study to Evaluate the Long-Term Safety of CLBR001, A Lentiviral Based Chimeric Antigen Receptor, In Patients With B-Cell Malignancies Previously Administered CLBR001
A Study to Evaluate the Long-Term Safety of CLBR001, A Lentiviral Based Chimeric Antigen Receptor, In Patients With B-Cell Malignancies Previously Administered CLBR001
Enrollment Status: Enrolling_by_invitation
Publish Date: January 10, 2025
Intervention Type: Combination product
Study Drugs: CLBR001 CAR-T Cells, SWI019
Study Phase: Phase 1
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
Enrollment Status: Completed
Publish Date: December 24, 2024
Intervention Type: Biological, Drug
Study Drugs: Axicabtagene Ciloleucel, Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders, Cyclophosphamide, Fludarabine
Study Phase: Phase 3
Expanded Access Program for Pirtobrutinib for Previously Treated B-Cell Cancers
Expanded Access Program for Pirtobrutinib for Previously Treated B-Cell Cancers
Enrollment Status: Approved_for_marketing
Publish Date: December 18, 2024
Intervention Type: Drug
A Phase 1, Open-label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Combination of CLBR001 and SWI019 in Patients With Relapsed/Refractory B-cell Malignancies
A Phase 1, Open-label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Combination of CLBR001 and SWI019 in Patients With Relapsed/Refractory B-cell Malignancies
Enrollment Status: Completed
Publish Date: August 20, 2024
Intervention Type: Combination product
Study Drugs: CLBR001 CAR-T Cells, SWI019
Study Phase: Phase 1
A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)
A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)
Enrollment Status: Completed
Publish Date: December 20, 2023
Intervention Type: Biological
Study Drug: Lisocabtagene maraleucel
Study Phase: Phase 2
A Pilot Study of Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma
A Pilot Study of Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: November 01, 2023
Intervention Type: Drug, Procedure
Study Drugs: Bendamustine, Rituximab, Cytarabine, Pegfilgrastim, Filgrastim
Study Phase: Phase 1
Phase Ib Study of Tisagenlecleucel in Combination With Pembrolizumab in Relapsed/Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) Patients.
Phase Ib Study of Tisagenlecleucel in Combination With Pembrolizumab in Relapsed/Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) Patients.
Enrollment Status: Completed
Publish Date: August 15, 2022
Intervention Type: Drug, Biological
Study Drugs: Tisagenlecleucel, Pembrolizumab
Study Phase: Phase 1
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
Enrollment Status: Terminated
Publish Date: July 15, 2022
Intervention Type: Drug, Biological
Study Drugs: IL-2, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
A Multicenter Phase I Dose-finding and Preliminary Efficacy Study of the Histone Deacetylase Inhibitor Romidepsin (Istodax) in Combination With Gemcitabine (Gemzar), Oxaliplatin (Eloxatin), and Dexamethasone for the Treatment of Adults With Relapsed/Refractory Aggressive Lymphomas
A Multicenter Phase I Dose-finding and Preliminary Efficacy Study of the Histone Deacetylase Inhibitor Romidepsin (Istodax) in Combination With Gemcitabine (Gemzar), Oxaliplatin (Eloxatin), and Dexamethasone for the Treatment of Adults With Relapsed/Refractory Aggressive Lymphomas
Enrollment Status: Completed
Publish Date: November 17, 2020
Intervention Type: Drug
Study Phase: Phase 1
An Investigator Sponsored Phase I/II Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
An Investigator Sponsored Phase I/II Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: March 13, 2020
Intervention Type: Procedure, Drug
Study Phase: Phase 1/Phase 2
A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant
A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant
Enrollment Status: Terminated
Publish Date: May 17, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 16 Less Clinical Trials

88 Total Publications

Cilta-cel salvages ide-cel failure in relapsed multiple myeloma by driving distinct immune responses.
Cilta-cel salvages ide-cel failure in relapsed multiple myeloma by driving distinct immune responses.
Journal: medRxiv : the preprint server for health sciences
Published: July 17, 2025
Similar Doctors
Distinguished in Midline Lethal Granuloma
Dr. Valentina Macrinici
Hematology Oncology | Hematology | Oncology
Distinguished in Midline Lethal Granuloma
Dr. Valentina Macrinici
Hematology Oncology | Hematology | Oncology

Ahp Specialty Care Nfp

3815 Highland Ave, 
Downers Grove, IL 
 (21.0 miles away)
630-275-5900
Languages Spoken:
English, Romanian, Russian
See accepted insurances
Accepting New Patients
Offers Telehealth

Valentina Macrinici is a Hematologist Oncology specialist and a Hematologist in Downers Grove, Illinois. Dr. Macrinici is rated as an Advanced provider by MediFind in the treatment of Midline Lethal Granuloma. Her top areas of expertise are Midline Lethal Granuloma, Anemia, Chronic Lymphocytic Leukemia (CLL), Familial Colorectal Cancer, and Bone Marrow Aspiration. Dr. Macrinici is currently accepting new patients.

Advanced in Midline Lethal Granuloma
Dr. Parameswaren Venugopal
Hematology | Oncology
Advanced in Midline Lethal Granuloma
Dr. Parameswaren Venugopal
Hematology | Oncology

Rush University Medical Group

1620 W Harrison St, 
Chicago, IL 
 (6.8 miles away)
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Parameswaren Venugopal is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Venugopal is rated as a Distinguished provider by MediFind in the treatment of Midline Lethal Granuloma. His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Venugopal is currently accepting new patients.

Advanced in Midline Lethal Granuloma
Dr. Nasir Shahab
Hematology Oncology | Hematology | Oncology
Advanced in Midline Lethal Granuloma
Dr. Nasir Shahab
Hematology Oncology | Hematology | Oncology

Du Page Medical Group Ltd

430 Warrenville Rd, Suite 210, 
Lisle, IL 
 (23.4 miles away)
630-432-6180
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nasir Shahab is a Hematologist Oncology specialist and a Hematologist in Lisle, Illinois. Dr. Shahab is rated as an Advanced provider by MediFind in the treatment of Midline Lethal Granuloma. His top areas of expertise are Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, Lung Cancer, and Familial Colorectal Cancer. Dr. Shahab is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Riedell's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 44 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile